Free tool
FAERS Monitor: Toviaz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022030 or its brand name (Toviaz, Fesoterodine Fumarate). Reports on generic versions are filed under their own applications.
Reports
10,803
Serious
6,068
56% of reports
Hospitalization
2,327
Death reported
439
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,689
- dry mouth823
- fall535
- off label use531
- fatigue527
- constipation508
- urinary retention502
- pain466
- headache435
- dizziness397
- condition aggravated349
- confusional state348
- rash340
- malaise334
- nausea327
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 80 |
| 2010 | 1,035 |
| 2011 | 544 |
| 2012 | 904 |
| 2013 | 1,023 |
| 2014 | 813 |
| 2015 | 618 |
| 2016 | 704 |
| 2017 | 601 |
| 2018 | 677 |
| 2019 | 825 |
| 2020 | 882 |
| 2021 | 619 |
| 2022 | 516 |
| 2023 | 358 |
| 2024 | 265 |
| 2025 | 225 |
| 2026 | 112 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,356 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| urinary retentionSignal | 502 | 29.7 | 27.3 | 13,720 |
| dry mouthSignal | 823 | 19.9 | 18.7 | 14,694 |
| constipationSignal | 508 | 4.5 | 4.2 | 1,412 |
| confusional stateSignal | 348 | 4.2 | 3.8 | 850 |
| fallSignal | 535 | 3.1 | 2.9 | 786 |
| drug ineffectiveSignal | 1,689 | 2.5 | 2.4 | 1,614 |
| condition aggravatedSignal | 349 | 2.2 | 2.0 | 241 |
| dizziness | 397 | 1.6 | 1.4 | 79 |
| rash | 340 | 1.5 | 1.4 | 61 |
| malaise | 334 | 1.5 | 1.3 | 53 |
| pain | 466 | 1.5 | 1.4 | 73 |
| headache | 435 | 1.4 | 1.2 | 41 |
| fatigue | 527 | 1.3 | 1.2 | 42 |
| off label use | 531 | 1.2 | 1.1 | 15 |
| nausea | 327 | 0.8 | 0.7 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.